The march of pluripotent stem cells in cardiovascular regenerative medicine

Haissam Abou-Saleh, Fouad A. Zouein, Ahmed El-Yazbi, Despina Sanoudou, Christophe M. Raynaud, Christopher Rao, Gianfranco Pintus, Hassan Dehaini, Ali H. Eid

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Cardiovascular disease (CVD) continues to be the leading cause of global morbidity and mortality. Heart failure remains a major contributor to this mortality. Despite major therapeutic advances over the past decades, a better understanding of molecular and cellular mechanisms of CVD as well as improved therapeutic strategies for the management or treatment of heart failure are increasingly needed. Loss of myocardium is a major driver of heart failure. An attractive approach that appears to provide promising results in reducing cardiac degeneration is stem cell therapy (SCT). In this review, we describe different types of stem cells, including embryonic and adult stem cells, and we provide a detailed discussion of the properties of induced pluripotent stem cells (iPSCs). We also present and critically discuss the key methods used for converting somatic cells to pluripotent cells and iPSCs to cardiomyocytes (CMs), along with their advantages and limitations. Integrating and non-integrating reprogramming methods as well as characterization of iPSCs and iPSC-derived CMs are discussed. Furthermore, we critically present various methods of differentiating iPSCs to CMs. The value of iPSC-CMs in regenerative medicine as well as myocardial disease modeling and cardiac regeneration are emphasized.

Original languageEnglish
Article number201
JournalStem Cell Research and Therapy
Volume9
Issue number1
DOIs
Publication statusPublished - 27 Jul 2018

Fingerprint

Induced Pluripotent Stem Cells
Pluripotent Stem Cells
Regenerative Medicine
Stem cells
Cardiac Myocytes
Heart Failure
Cardiovascular Diseases
Stem Cells
Adult Stem Cells
Mortality
Embryonic Stem Cells
Cell- and Tissue-Based Therapy
Treatment Failure
Cardiomyopathies
Regeneration
Myocardium
Morbidity
Therapeutics

Keywords

  • Cardiomyocytes
  • Cardiovascular disease
  • Heart failure
  • iPSCs
  • Regenerative medicine
  • Stem cell therapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Cell Biology

Cite this

Abou-Saleh, H., Zouein, F. A., El-Yazbi, A., Sanoudou, D., Raynaud, C. M., Rao, C., ... Eid, A. H. (2018). The march of pluripotent stem cells in cardiovascular regenerative medicine. Stem Cell Research and Therapy, 9(1), [201]. https://doi.org/10.1186/s13287-018-0947-5

The march of pluripotent stem cells in cardiovascular regenerative medicine. / Abou-Saleh, Haissam; Zouein, Fouad A.; El-Yazbi, Ahmed; Sanoudou, Despina; Raynaud, Christophe M.; Rao, Christopher; Pintus, Gianfranco; Dehaini, Hassan; Eid, Ali H.

In: Stem Cell Research and Therapy, Vol. 9, No. 1, 201, 27.07.2018.

Research output: Contribution to journalReview article

Abou-Saleh, H, Zouein, FA, El-Yazbi, A, Sanoudou, D, Raynaud, CM, Rao, C, Pintus, G, Dehaini, H & Eid, AH 2018, 'The march of pluripotent stem cells in cardiovascular regenerative medicine', Stem Cell Research and Therapy, vol. 9, no. 1, 201. https://doi.org/10.1186/s13287-018-0947-5
Abou-Saleh, Haissam ; Zouein, Fouad A. ; El-Yazbi, Ahmed ; Sanoudou, Despina ; Raynaud, Christophe M. ; Rao, Christopher ; Pintus, Gianfranco ; Dehaini, Hassan ; Eid, Ali H. / The march of pluripotent stem cells in cardiovascular regenerative medicine. In: Stem Cell Research and Therapy. 2018 ; Vol. 9, No. 1.
@article{553605709a9b408dacd6ac10099c3201,
title = "The march of pluripotent stem cells in cardiovascular regenerative medicine",
abstract = "Cardiovascular disease (CVD) continues to be the leading cause of global morbidity and mortality. Heart failure remains a major contributor to this mortality. Despite major therapeutic advances over the past decades, a better understanding of molecular and cellular mechanisms of CVD as well as improved therapeutic strategies for the management or treatment of heart failure are increasingly needed. Loss of myocardium is a major driver of heart failure. An attractive approach that appears to provide promising results in reducing cardiac degeneration is stem cell therapy (SCT). In this review, we describe different types of stem cells, including embryonic and adult stem cells, and we provide a detailed discussion of the properties of induced pluripotent stem cells (iPSCs). We also present and critically discuss the key methods used for converting somatic cells to pluripotent cells and iPSCs to cardiomyocytes (CMs), along with their advantages and limitations. Integrating and non-integrating reprogramming methods as well as characterization of iPSCs and iPSC-derived CMs are discussed. Furthermore, we critically present various methods of differentiating iPSCs to CMs. The value of iPSC-CMs in regenerative medicine as well as myocardial disease modeling and cardiac regeneration are emphasized.",
keywords = "Cardiomyocytes, Cardiovascular disease, Heart failure, iPSCs, Regenerative medicine, Stem cell therapy",
author = "Haissam Abou-Saleh and Zouein, {Fouad A.} and Ahmed El-Yazbi and Despina Sanoudou and Raynaud, {Christophe M.} and Christopher Rao and Gianfranco Pintus and Hassan Dehaini and Eid, {Ali H.}",
year = "2018",
month = "7",
day = "27",
doi = "10.1186/s13287-018-0947-5",
language = "English",
volume = "9",
journal = "Stem Cell Research and Therapy",
issn = "1757-6512",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The march of pluripotent stem cells in cardiovascular regenerative medicine

AU - Abou-Saleh, Haissam

AU - Zouein, Fouad A.

AU - El-Yazbi, Ahmed

AU - Sanoudou, Despina

AU - Raynaud, Christophe M.

AU - Rao, Christopher

AU - Pintus, Gianfranco

AU - Dehaini, Hassan

AU - Eid, Ali H.

PY - 2018/7/27

Y1 - 2018/7/27

N2 - Cardiovascular disease (CVD) continues to be the leading cause of global morbidity and mortality. Heart failure remains a major contributor to this mortality. Despite major therapeutic advances over the past decades, a better understanding of molecular and cellular mechanisms of CVD as well as improved therapeutic strategies for the management or treatment of heart failure are increasingly needed. Loss of myocardium is a major driver of heart failure. An attractive approach that appears to provide promising results in reducing cardiac degeneration is stem cell therapy (SCT). In this review, we describe different types of stem cells, including embryonic and adult stem cells, and we provide a detailed discussion of the properties of induced pluripotent stem cells (iPSCs). We also present and critically discuss the key methods used for converting somatic cells to pluripotent cells and iPSCs to cardiomyocytes (CMs), along with their advantages and limitations. Integrating and non-integrating reprogramming methods as well as characterization of iPSCs and iPSC-derived CMs are discussed. Furthermore, we critically present various methods of differentiating iPSCs to CMs. The value of iPSC-CMs in regenerative medicine as well as myocardial disease modeling and cardiac regeneration are emphasized.

AB - Cardiovascular disease (CVD) continues to be the leading cause of global morbidity and mortality. Heart failure remains a major contributor to this mortality. Despite major therapeutic advances over the past decades, a better understanding of molecular and cellular mechanisms of CVD as well as improved therapeutic strategies for the management or treatment of heart failure are increasingly needed. Loss of myocardium is a major driver of heart failure. An attractive approach that appears to provide promising results in reducing cardiac degeneration is stem cell therapy (SCT). In this review, we describe different types of stem cells, including embryonic and adult stem cells, and we provide a detailed discussion of the properties of induced pluripotent stem cells (iPSCs). We also present and critically discuss the key methods used for converting somatic cells to pluripotent cells and iPSCs to cardiomyocytes (CMs), along with their advantages and limitations. Integrating and non-integrating reprogramming methods as well as characterization of iPSCs and iPSC-derived CMs are discussed. Furthermore, we critically present various methods of differentiating iPSCs to CMs. The value of iPSC-CMs in regenerative medicine as well as myocardial disease modeling and cardiac regeneration are emphasized.

KW - Cardiomyocytes

KW - Cardiovascular disease

KW - Heart failure

KW - iPSCs

KW - Regenerative medicine

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=85050742962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050742962&partnerID=8YFLogxK

U2 - 10.1186/s13287-018-0947-5

DO - 10.1186/s13287-018-0947-5

M3 - Review article

C2 - 30053890

AN - SCOPUS:85050742962

VL - 9

JO - Stem Cell Research and Therapy

JF - Stem Cell Research and Therapy

SN - 1757-6512

IS - 1

M1 - 201

ER -